Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer.

Buttarelli M, Babini G, Raspaglio G, Filippetti F, Battaglia A, Ciucci A, Ferrandina G, Petrillo M, Marino C, Mancuso M, Saran A, Villani ME, Desiderio A, D'Ambrosio C, Scaloni A, Scambia G, Gallo D.

J Exp Clin Cancer Res. 2019 Jun 26;38(1):279. doi: 10.1186/s13046-019-1268-y.

2.

Preoperative Anti-Class III β-Tubulin Antibodies As Relevant Clinical Biomarkers in Ovarian Cancer.

Martinelli E, Fattorossi A, Battaglia A, Petrillo M, Raspaglio G, Zannoni GF, Fanelli M, Gallo D, Scambia G.

Transl Oncol. 2018 Apr;11(2):358-365. doi: 10.1016/j.tranon.2018.01.016. Epub 2018 Feb 20.

3.

Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer.

Donato MD, Fanelli M, Mariani M, Raspaglio G, Pandya D, He S, Fiedler P, Petrillo M, Scambia G, Ferlini C.

Am J Cancer Res. 2015 May 15;5(6):1862-77. eCollection 2015.

4.

Role and prognostic significance of the epithelial-mesenchymal transition factor ZEB2 in ovarian cancer.

Prislei S, Martinelli E, Zannoni GF, Petrillo M, Filippetti F, Mariani M, Mozzetti S, Raspaglio G, Scambia G, Ferlini C.

Oncotarget. 2015 Aug 7;6(22):18966-79.

5.

Sox9 and Hif-2α regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.

Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, Filippetti F, Mozzetti S, Prislei S, Zannoni GF, Scambia G, Ferlini C.

Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.

PMID:
24661907
6.

MiR-200c and HuR in ovarian cancer.

Prislei S, Martinelli E, Mariani M, Raspaglio G, Sieber S, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

BMC Cancer. 2013 Feb 8;13:72. doi: 10.1186/1471-2407-13-72.

7.

Gli family transcription factors are drivers of patupilone resistance in ovarian cancer.

Mozzetti S, Martinelli E, Raspaglio G, Prislei S, De Donato M, Filippetti F, Shahabi S, Scambia G, Ferlini C.

Biochem Pharmacol. 2012 Dec 1;84(11):1409-18. doi: 10.1016/j.bcp.2012.08.019. Epub 2012 Sep 1.

PMID:
22964220
8.

RON and cisplatin resistance in ovarian cancer cell lines.

Prislei S, Mariani M, Raspaglio G, Mozzetti S, Filippetti F, Ferrandina G, Scambia G, Ferlini C.

Oncol Res. 2010;19(1):13-22.

PMID:
21141737
9.

HuR regulates beta-tubulin isotype expression in ovarian cancer.

Raspaglio G, De Maria I, Filippetti F, Martinelli E, Zannoni GF, Prislei S, Ferrandina G, Shahabi S, Scambia G, Ferlini C.

Cancer Res. 2010 Jul 15;70(14):5891-900. doi: 10.1158/0008-5472.CAN-09-4656. Epub 2010 Jun 29.

10.

Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77.

Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C, Mozzetti S, Gallo D, Persico M, Fattorusso C, Campiani G, Scambia G.

Cancer Res. 2009 Sep 1;69(17):6906-14. doi: 10.1158/0008-5472.CAN-09-0540. Epub 2009 Aug 11.

11.

Antiproliferative and antiangiogenic effects of the benzophenanthridine alkaloid sanguinarine in melanoma.

De Stefano I, Raspaglio G, Zannoni GF, Travaglia D, Prisco MG, Mosca M, Ferlini C, Scambia G, Gallo D.

Biochem Pharmacol. 2009 Dec 1;78(11):1374-81. doi: 10.1016/j.bcp.2009.07.011. Epub 2009 Jul 28.

PMID:
19643088
12.

Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work?

Ferlini C, Raspaglio G, Cicchillitti L, Mozzetti S, Prislei S, Bartollino S, Scambia G.

Curr Cancer Drug Targets. 2007 Dec;7(8):704-12. Review.

PMID:
18220531
13.

From plasma membrane to cytoskeleton: a novel function for semaphorin 6A.

Prislei S, Mozzetti S, Filippetti F, De Donato M, Raspaglio G, Cicchillitti L, Scambia G, Ferlini C.

Mol Cancer Ther. 2008 Jan;7(1):233-41. doi: 10.1158/1535-7163.MCT-07-0390. Epub 2008 Jan 9.

14.

Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region.

Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L, Mozzetti S, Scambia G, Ferlini C.

Gene. 2008 Feb 15;409(1-2):100-8. doi: 10.1016/j.gene.2007.11.015. Epub 2007 Dec 3.

PMID:
18178340
15.

Bcl-2 down-regulation and tubulin subtype composition are involved in resistance of ovarian cancer cells to vinflunine.

Estève MA, Carré M, Bourgarel-Rey V, Kruczynski A, Raspaglio G, Ferlini C, Braguer D.

Mol Cancer Ther. 2006 Nov;5(11):2824-33.

16.

Microsatellite instability is not related to response to cisplatin-based chemotherapy in cervical cancer.

Ercoli A, Ferrandina G, Genuardi M, Zannoni GF, Cicchillitti L, Raspaglio G, Carrara S, Mancuso S, Scambia G.

Int J Gynecol Cancer. 2005 Mar-Apr;15(2):308-11.

17.

The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.

Ferlini C, Raspaglio G, Mozzetti S, Cicchillitti L, Filippetti F, Gallo D, Fattorusso C, Campiani G, Scambia G.

Cancer Res. 2005 Mar 15;65(6):2397-405.

18.

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G.

Clin Cancer Res. 2005 Jan 1;11(1):298-305.

19.

Thiocolchicine dimers: a novel class of topoisomerase-I inhibitors.

Raspaglio G, Ferlini C, Mozzetti S, Prislei S, Gallo D, Das N, Scambia G.

Biochem Pharmacol. 2005 Jan 1;69(1):113-21.

PMID:
15588720
20.
21.

Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.

Gallo D, Giacomelli S, Ferlini C, Raspaglio G, Apollonio P, Prislei S, Riva A, Morazzoni P, Bombardelli E, Scambia G.

Eur J Cancer. 2003 Nov;39(16):2403-10.

PMID:
14556934
22.

Bcl-2 down-regulation is a novel mechanism of paclitaxel resistance.

Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO, Scambia G.

Mol Pharmacol. 2003 Jul;64(1):51-8.

PMID:
12815160
23.

Microsatellite instability is an independent indicator of recurrence in sporadic stage I-II endometrial adenocarcinoma.

Fiumicino S, Ercoli A, Ferrandina G, Hess P, Raspaglio G, Genuardi M, Rovella V, Bellacosa A, Cicchillitti L, Mancuso S, Bignami M, Scambia G.

J Clin Oncol. 2001 Feb 15;19(4):1008-14.

PMID:
11181663
24.

Activity of cisplatin and ICI 182,780 on estrogen receptor negative ovarian cancer cells: cell cycle and cell replication rate perturbation, chromatin texture alteration and apoptosis induction.

Ercoli A, Battaglia A, Raspaglio G, Fattorossi A, Alimonti A, Petrucci F, Caroli S, Mancuso S, Scambia G.

Int J Cancer. 2000 Jan 1;85(1):98-103.

25.

hMSH2 and GTBP expression in advanced stage epithelial ovarian cancer.

Ercoli A, Ferrandina G, Raspaglio G, Marone M, Maggiano N, Del Mastro P, Benedetti Panici P, Mancuso S, Scambia G.

Br J Cancer. 1999 Jul;80(10):1665-71.

26.

Comparative study on the induction of cytostasis and apoptosis by ICI 182,780 and tamoxifen in an estrogen receptor-negative ovarian cancer cell line.

Ercoli A, Scambia G, Fattorossi A, Raspaglio G, Battaglia A, Cicchillitti L, Malorni W, Rainaldi G, Benedetti Panici P, Mancuso S.

Int J Cancer. 1998 Mar 30;76(1):47-54.

27.

Two pathways for base excision repair in mammalian cells.

Frosina G, Fortini P, Rossi O, Carrozzino F, Raspaglio G, Cox LS, Lane DP, Abbondandolo A, Dogliotti E.

J Biol Chem. 1996 Apr 19;271(16):9573-8.

28.

Analysis of DNA alkylation damage and repair in mammalian cells by the comet assay.

Fortini P, Raspaglio G, Falchi M, Dogliotti E.

Mutagenesis. 1996 Mar;11(2):169-75.

PMID:
8671734

Supplemental Content

Loading ...
Support Center